Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501658 | 0.87 | NR3C1 (0.43) | NR3C1PGRARLMNARAB9A | |
| SCHEMBL87129 | 0.73 | ACHE (0.43) | NR3C1LMNARAB9AALDH1A1ACHE | |
| SCHEMBL20552496 | 0.73 | AR (0.44) | NR3C1ARLMNAALDH1A1ACHE | |
| SCHEMBL11394821 | 0.73 | NQO1 (0.43) | LMNARAB9AALDH1A1ACHE | |
| SCHEMBL3901331 | 0.73 | AR (0.44) | NR3C1ARLMNAALDH1A1ACHE | |
| SCHEMBL675985 | 0.73 | KDM4E (0.62) | ARLMNAALDH1A1ACHE | |
| SCHEMBL7106401 | 0.71 | ALDH1A1 (0.73) | NR3C1LMNAFADS1ALDH1A1MAOB | |
| SCHEMBL3788674 | 0.71 | SIRT1 (0.47) | NR3C1PGRNR3C2RAB9AALDH1A1 | |
| SCHEMBL20752049 | 0.70 | NR3C1 (0.37) | NR3C1PGRNR3C2ARLMNA | |
| SCHEMBL10495516 | 0.69 | AKT1 (0.48) | NR3C1LMNAALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3180318-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, HTR5A, TRPV5 | NR3C1 339/4885PGR 1408/4885NR3C2 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.